Silhouette

George E Wright

Glsynthesis, Inc.

Employers

Affiliated Awards

Award Title Agency Phase Award amount Start Date End Date
Oral prodrug of a novel antiviral that blocks neuronal reactivation of HSV
Glsynthesis, Inc.
Principal Investigator
HHS 1 $300K 09/01/12 08/31/13
Preclinical development of a novel antibacterial for Clostridium difficile diseas
Glsynthesis, Inc.
Principal Investigator
HHS 2 $1.42MM 03/01/12 02/28/13
Preclinical development of a novel antibacterial for Clostridium difficile diseas
Glsynthesis, Inc.
Principal Investigator
HHS 2 $935K 03/01/11 02/29/12
Analogs of GTP as novel inhibitors of bacterial c-di-GMP-synthesizing enzymes
Glsynthesis, Inc.
Principal Investigator
HHS 1 $300K 06/15/10 05/31/12
Preclinical development of a novel antibacterial for Clostridium difficile diseas
Glsynthesis, Inc.
Principal Investigator
HHS 2 $620K 03/15/10 02/28/11
Hybrid Molecules Designed to Enhance Antibiotic Activity
Glsynthesis, Inc.
Principal Investigator
HHS 2 $39.9K 06/05/09 10/31/09
Hybrid Molecules Designed to Enhance Antibiotic Activity
Glsynthesis, Inc.
Principal Investigator
HHS 2 $967K 05/01/08 04/30/10
Hybrid Molecules Designed to Enhance Antibiotic Activity
Glsynthesis, Inc.
Principal Investigator
HHS 2 $940K 05/01/07 04/30/08
Hybrid Molecules Designed to Enhance Antibiotic Activity
Glsynthesis, Inc.
Principal Investigator
HHS 2 $938K 05/01/06 04/30/07
DNA Polymerase IIIe, A New Antibiotic Target
Glsynthesis, Inc.
Principal Investigator
HHS 2 $907K 04/01/06 03/31/08
High Throughput Membrane-Water Partition Coefficients
Glsynthesis, Inc.
Principal Investigator
HHS 1 $255K 09/15/05 09/30/07
Fluorosome Technique for Drug Permeability Studies
Glsynthesis, Inc.
Principal Investigator
HHS 2 $444K 08/01/05 07/31/07
DNA Polymerase IIIe, A New Antibiotic Target
Glsynthesis, Inc.
Principal Investigator
HHS 2 $944K 04/01/05 03/31/06
Fluorosome Technique for Drug Permeability Studies
Glsynthesis, Inc.
Principal Investigator
HHS 2 $489K 08/09/04 07/31/05
Antiviral Drugs for Treatment of Herpes B Infections
Glsynthesis, Inc.
Principal Investigator
HHS 1 $254K 05/15/03 05/14/05
Hybrid Molecules Designed to Enhance Antibiotic Activity
Glsynthesis, Inc.
Principal Investigator
HHS 2 $477K 05/01/03 04/30/05
DNA Polymerase IIIE, A New Antibiotic Target
Glsynthesis, Inc.
Principal Investigator
HHS 1 $307K 07/01/02 06/30/03
Hybrid Molecules Designed to Enhance Antibiotic Activity
Glsynthesis, Inc.
Principal Investigator
HHS 2 $500K 05/01/02 04/30/03
Drugs to Prevent Recurrent Herpesvirus Infections
Glsynthesis, Inc.
Principal Investigator
HHS 2 $417K 05/01/01 04/30/03
Gram+ Antimicrobials Targeted to DNA Polymerase Iii
Glsynthesis, Inc.
Principal Investigator
HHS 2 $550K 07/01/00 06/30/02
Drugs to Prevent Recurrent Herpesvirus Infections
Glsynthesis, Inc.
Principal Investigator
HHS 2 $364K 05/01/00 04/30/01
Gram+ Antimicrobials Targeted to DNA Polymerase Iii
Glsynthesis, Inc.
Principal Investigator
HHS 2 $0.0 07/15/99 06/30/00
Antiangiogenesis by Thymidine Phosphorylase Inhibitors
Glsynthesis, Inc.
Principal Investigator
HHS 1 $0.0 01/01/99 06/30/00
Drugs to Prevent Recurrent Herpesvirus Infections
Glsynthesis, Inc.
Principal Investigator
HHS 1 $0.0 03/01/98 08/31/99
Gram+ Antimicrobials Targeted to DNA Polymerase Iii
Glsynthesis, Inc.
Principal Investigator
HHS 1 $0.0 02/01/98 07/14/99